The role of PET/CT in disease activity assessment in patients with large vessel vasculitis

被引:29
|
作者
Galli, Elena [1 ,2 ]
Muratore, Francesco [1 ]
Mancuso, Pamela [3 ]
Boiardi, Luigi [1 ]
Marvisi, Chiara [1 ,2 ]
Besutti, Giulia [4 ]
Spaggiari, Lucia [4 ]
Casali, Massimiliano [5 ]
Versari, Annibale [5 ]
Rossi, Paolo Giorgi [3 ]
Salvarani, Carlo [1 ,2 ]
机构
[1] Azienda Unita Sanitaria Locale IRCCS Reggio Emili, Rheumatol Unit, Reggio Emilia, Italy
[2] Univ Modena & Reggio Emilia, Rheumatol Unit, Modena, Italy
[3] Azienda Unita Sanitaria Locale IRCCS Reggio Emili, Epidemiol Unit, Reggio Emilia, Italy
[4] Azienda Unita Sanitaria Locale IRCCS Reggio Emili, Radiol Unit, Reggio Emilia, Italy
[5] Azienda Unita Sanitaria Locale IRCCS Reggio Emili, Nucl Med Unit, Reggio Emilia, Italy
关键词
PET; CT; PETVAS; Takayasu arteritis; GCA; large vessel vasculitis; GIANT-CELL ARTERITIS; EMISSION-TOMOGRAPHY; TAKAYASU ARTERITIS; F-18-FDG PET/CT; FOLLOW-UP; INFLAMMATION; TOCILIZUMAB;
D O I
10.1093/rheumatology/keac125
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the accuracy of PET/CT and of PET vascular activity score (PETVAS) in assessing disease activity and the ability of PETVAS in predicting relapses in a large single-centre cohort of patients with large vessel vasculitis (LVV). Methods We conducted a retrospective cohort study of prospectively collected data of consecutive patients diagnosed with LVV who underwent at least one PET/CT scan between 2007 and 2020. The nuclear medicine physician's interpretation of each PET/CT scan (active/inactive vasculitis) was compared with disease activity clinical judgement (active disease/remission). For each PET/CT scan, the PETVAS score was calculated and its accuracy in assessing disease activity was evaluated. The ability of PETVAS in predicting subsequent relapses was evaluated. Results A total of 100 consecutive LVV patients (51 large vessel GCA, 49 Takayasu arteritis) underwent a total of 476 PET/CT scans over a mean follow-up period of 97.5 months. Physician-determined PET/CT grading was able to distinguish between clinically active and inactive LVV with a sensitivity of 60% (95% CI 50.9, 68.7) and specificity of 80.1% (95% CI 75.5, 84.1); the area under the curve (AUC) was 0.70 (95% CI 0.65, 0.75). PETVAS was associated with disease activity, with an age and sex-adjusted odds ratio for active disease of 1.15 (95% CI 1.11, 1.19). A PETVAS >= 10 provided 60.8% sensitivity and 80.6% specificity in differentiating between clinically active and inactive LVV; the AUC was 0.73 (95% CI 0.68, 0.79). PETVAS was not associated with subsequent relapses, with an age and sex-adjusted hazard ratio of 1.04 (95% CI 0.97, 1.11). Conclusions The visual PET/CT grading scale and PETVAS had moderate accuracy to distinguish active LVV from remission. PETVAS did not predict disease relapses.
引用
收藏
页码:4809 / 4816
页数:8
相关论文
共 50 条
  • [1] The role of PET/CT in disease activity assessment in patients with large vessel vasculitis
    Galli, Elena
    Pipitone, Nicolo
    Salvarani, Carlo
    CURRENT OPINION IN RHEUMATOLOGY, 2023, 35 (03) : 194 - 200
  • [2] The Role of PET in the Diagnosis and Disease Activity Assessment in Large Vessel Vasculitis
    Marvisi, Chiara
    Galli, Elena
    Ricordi, Caterina
    Durmo, Rexhep
    Roncali, Massimo
    Muratore, Francesco
    Salvarani, Carlo
    Versari, Annibale
    HEMATO, 2023, 4 (04): : 321 - 330
  • [3] THE ROLE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET/CT) IN DISEASE ACTIVITY ASSESSMENT IN PATIENTS WITH LARGE VESSEL VASCULITIS
    Galli, E.
    Muratore, F.
    Boiardi, L.
    Casali, M. I.
    Versari, A.
    Besutti, G.
    Spaggiari, L.
    Mancuso, P.
    Rossi, P. Giorgi
    Salvarani, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 37 - 37
  • [4] FDG PET in large vessel vasculitis: disease activity assessment
    Versari, A.
    Magnani, L.
    Di Paolo, M.
    Pazzola, G.
    Roncali, M.
    Boiardi, L.
    Fraternali, A.
    Salvarani, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S238 - S238
  • [5] EVALUATION OF DISEASE ACTIVITY USING FDG PET-CT IN PATIENTS WITH LARGE VESSEL VASCULITIS
    Pazzola, G.
    Magnani, L.
    Boiardi, L.
    Pipitone, N.
    Muratore, F.
    Versari, A.
    Formisano, D.
    Addimanda, O.
    Meliconi, R.
    Pulsatelli, L.
    Bajocchi, G.
    Catanoso, M.
    Padovano, I.
    Possemato, N.
    Lo Gullo, A.
    Salvarani, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 158 - 158
  • [6] Evaluation of Disease Activity Using FDG PET-CT in Patients with Large Vessel Vasculitis
    Pazzola, Giulia
    Magnani, Luca
    Boiardi, Luigi
    Pipitone, Nicolo
    Versari, Annibale
    Formisano, Debora
    Addimanda, Olga
    Meliconi, Riccardo
    Pulsatelli, Lia
    Bajocchi, Gianluigi
    Macchioni, Pierluigi
    Catanoso, Maria Grazia
    Possemato, Niccolo
    Padovano, Ilaria
    Lo Gullo, Alberto
    Salvarani, Carlo
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S996 - S996
  • [7] Disease activity assessment in large vessel vasculitis
    Magnani, L.
    Versari, A.
    Salvo, D.
    Casali, M.
    Germano, G.
    Meliconi, R.
    Pulsatelli, L.
    Formisano, D.
    Bajocchi, G.
    Pipitone, N.
    Boiardi, L.
    Salvarani, C.
    REUMATISMO, 2011, 63 (02) : 86 - 90
  • [8] Activity Assessment of Large Vessel Vasculitis with F18-FDG-PET(/CT)
    Schramm, N.
    Ingenhoff, J.
    Dechant, C.
    Proft, F.
    Schulze-Koops, H.
    Hoffmann, U.
    Rominger, A.
    Czihal, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S378 - S378
  • [9] FDG PET/CT in large vessel vasculitis: correlation between SUV and disease activity
    Casali, M.
    Pazzola, G.
    Muratore, F.
    Sollini, M.
    Boiardi, L.
    Di Paolo, M. L.
    Froio, A.
    Pipitone, N.
    Salvarani, C.
    Versari, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S166 - S167
  • [10] A role of FDG PET/CT for Response Assessment in Large Vessel Disease?
    Treglia, Giorgio
    Albano, Domenico
    Dondi, Francesco
    Bertagna, Francesco
    Gheysens, Olivier
    SEMINARS IN NUCLEAR MEDICINE, 2023, 53 (01) : 78 - 85